Tirzepatide in PWS, HO and GNSO

Description

This study is for the following individuals:

* Age 18-26.
* Have Prader-Willi Syndrome, Hypothalamic Obesity, or Obesity unrelated to a genetic syndrome or medical condition.
* Have a BMI in the obesity range

If you/your child decide to take part in the research study, you/your child would participate in the study for approximately 56-60 weeks. During this time the following can be expected:

* Receive tirzepatide for once-weekly dosing.
* Complete 6 in-person SCH study visits
* Complete 4 telehealth visits.
* Complete the following research procedures:

* Medical Record Review
* Vital Signs
* Anthropometry (e.g., height, weight, waist measurements)
* Physical Exams
* Laboratory Tests (e.g., fasting blood draws, urine test)
* Dual-Energy Absorptiometry (DXA) scans
* Questionnaires